Parenteral Treprostinil

ApprovedSmall molecule

Parenteral Treprostinil is one of 40 small molecule programs targeting Pulmonary Arterial Hypertension. It is currently in Approved.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

Pulmonary Arterial HypertensionActive, not recruiting

Pulmonary Arterial HypertensionApproved

Active, not recruiting

Competition

Competitive Landscape

179 competitors in Pulmonary Arterial Hypertension

#DrugCompanyPhaseTrials

Gleevec

Novartis

Phase 3

6 2

Reata

Biogen

Phase 3

1 3

Levitra

Bayer

Phase 3

1 4

Aurlumyn

BBTG International Inc.

Phase 3

8 5

Flolan

Johnson & Johnson

Phase 3

1 6

Zesly

MMezzion Pharma Co. Ltd

Phase 3

1 7

Atrovent

Inhaled Iloprost

1 9

Rituxan

Roche

Phase 2

1 10

Medrol

Pfizer

Phase 2

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q2 2028

Post-ApprovalActive, not recruiting

Pulmonary Arterial Hypertension

NCT05203510

Clinical

Trials by Indication[1]

Adult1 trial

Safety of Transition From Selexipag to Remodulin® Then Oral Treprostinil in Symptomatic Adult PAH

Withdrawn· United Therapeutics logo

United Therapeutics·Phase 2·NCT03016468

Pulmonary Arterial Hypertension1 trial

A Study of a Mean Pulmonary Artery Pressure-Targeted Approach With Early and Rapid Treprostinil Therapy to Reverse Right Ventricular Remodeling in Participants With Pulmonary Arterial Hypertension

Active, not recruiting· United Therapeutics logo

United Therapeutics·Phase 4·NCT05203510·52 enrolled

Sources

References

[1]
ClinicalTrials.gov — 2 trial records for Parenteral Treprostinil. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — Parenteral Treprostinil compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for Parenteral Treprostinil. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — United Therapeutics company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Approved[1]
Company: United Therapeutics

Parenteral Treprostinil

Status by Indication[3][1]

Competitive Landscape

Expected Milestones

Q2 2028

Trials by Indication[1]

Adult1 trial

Pulmonary Arterial Hypertension1 trial

References

Drug Info

Quick Facts

Related News